---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030284"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:37:25.102636+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M

## Summary
- Operating income turned negative at $(60), down 101.5% vs prior year.
- Non-GAAP adj. operating income ex unusual items fell 29.1% to $11.2M.
- Clinical Genomics down 15.7% organic on Sema4 loss ($8.2M annual headwind).
- Biopharm Development revenues fell 24.4% organic, consumables up 4.7%.
- Cost actions expected to save ~$2M annually starting in Q3; GKE acquisition closed Oct 2023.

## SEC filing metadata
- accession: 0001437749-23-030284
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/0001437749-23-030284-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/mlab20231103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030284
- JSON: https://secwatch.observer/filing/0001437749-23-030284.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030284.txt

## Key facts
- Earnings Releases
  MESA LABORATORIES INC /CO/ reported second fiscal quarter ended September 30, 2023 results: revenue $53,165, net income $(1,230), EPS $(0.23) per diluted share.
  - Period: second fiscal quarter ended September 30, 2023
  - Revenue: $53,165
  - Net income: $(1,230)
  - EPS: $(0.23) per diluted share
  - Result: reported results
  source text: our Clinical Genomics division early in 3Q23 but was better than the first quarter for both revenues and AOI excluding unusual items. Total revenues for the second quarter were $53,165, which resulted in an organic revenue (“organic”) decline of 9.6% versus the same quarter in the prior year (“2Q23”), or a 5.0% sequential increase when compared to the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/0001437749-23-030284-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.